A new clinical study shows the effects of a S-AdenosylMethionine-based dietary supplement (SAMe 200 mg/die – Adonat SAMe ingredient manufactured by the biotech company Gnosis SpA – plus vitamin B-complex) in improving mild and moderate depressive symptoms.
The nutraceutical product tested is commercialised by Abela Pharm (Belgrade, Serbia) under the brand name of Tensilen.
The study included 60 patients randomly allocated into two groups. The study group was treated with SAMe-vitamin B complex while the control group was administered a placebo, once a day for three months.
To assess the efficacy in relieving symptoms of depression, well-established research ratings were used as evaluators, such as the Hamilton Depression rating scale (HAMD17) and the Clinical Global Impression-Severity scale (CGI-S). Measuring symptoms’ severity is based on the Clinical Global Impression-Improvement scale (CGI-I), as well as assessments on whether there are improvements or decreases after treatment, relative to the baseline state.
The results of the study are very positive for all the different kinds of tests with statistically significant differences between the study group and the control group.
This clinical study confirms the renewed interest of SAMe in the treatment of mood and as adjuvant in depressive symptoms.
A recent review of Sharma et al 2017 has taken into consideration 132 studies – 115 clinical and 17 preclinical – and has provided evidence that oral doses of SAMe are superior to placebo in ameliorating the quality of life for depressed people.